1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,570 | 6,600 | 14:39 | |
| 0,000 | 0,000 | 14:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.12. | ADOCIA Announces its Financial Calendar for 2026 | 288 | Business Wire | Regulatory News:
Adocia (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment... ► Artikel lesen | |
| 08.12. | ADOCIA SA: Number of Shares and Voting Rights of ADOCIA as of December 8th, 2025 | 278 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen | |
| 04.12. | ADOCIA Announces the Completion of a €10 Million Fundraising | 371 | Business Wire | Fundraising of a total amount of €10 million in gross proceeds through the issuance of a total number of 1,262,626 new shares, each with one share warrant attached, subscribed by CVI Investments... ► Artikel lesen | |
| 14.11. | Number of Shares and Voting Rights of ADOCIA as of October 31st, 2025 | 314 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen | |
| 12.11. | ADOCIA Announces Filing of Patent for New Long-Acting Peptides Platform in Diabetes and Obesity - AdoXLong - and Provides an Update on its BioChaperone Platform | 295 | Business Wire | New technological platform of chemical modification of acylated peptides to extend their duration of action to at least one month, AdoXLong
Patent filing with an initial application on semaglutide... ► Artikel lesen | |
| 15.10. | ADOCIA Reports Third Quarter 2025 Financial Results and Provides a Business Update | 434 | Business Wire | Cash position of €13.4 million as of September 30, 2025 US$10 million milestone payment from partner Tonghua Dongbao and 2024 Research Tax Credit of €2.8 million received in July 2025 ... ► Artikel lesen | |
| 15.10. | ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone Lispro (THDB0206 injection) in people with T1D | 480 | Business Wire | This Phase 3 clinical trial on BioChaperone Lispro (THDB0206 injection) conducted in China in people with Type 1 Diabetes, successfully demonstrated, in comparison with standard of care Humalog:
... ► Artikel lesen | |
| ADOCIA Aktie jetzt für 0€ handeln | |||||
| 10.10. | Number of Shares and Voting Rights of ADOCIA as of September 30th, 2025 | 288 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen | |
| 25.09. | ADOCIA Announces First Half 2025 Financial Results and Provides a Business Update | 444 | Business Wire | Cash position of €7.1m (million) as of June 30, 2025 following successful completion of €9.7m private placement in February 2025
Cash runway secured until Q2 2026 considering the US$10... ► Artikel lesen | |
| 11.09. | Number of Shares and Voting Rights of ADOCIA as of August 31st, 2025 | 334 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen | |
| 03.09. | ADOCIA Announces Oral Presentations on AdoShell and BioChaperone at EASD, ESB and PODD 2025 Annual Meetings | 2.079 | Business Wire | Regulatory News:
Adocia (Euronext Paris: FR0011184241 ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions... ► Artikel lesen | |
| 19.08. | Number of Shares and Voting Rights of ADOCIA as of July 31st, 2025 | 385 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen | |
| 25.07. | ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone Lispro (THDB0206 injection) in People with T2D | 1.007 | Business Wire | This Phase 3 clinical trial on BioChaperone Lispro (THDB0206 injection) conducted in China in people with Type 2 diabetes, successfully demonstrated, in comparison with standard of care Humalog:
... ► Artikel lesen | |
| 23.07. | ADOCIA Reports Second Quarter 2025 Financial Results and Provides a Business Update | 644 | Business Wire | Cash position of €7.1 million as of June 30, 2025
US$10 million milestone payment from partner Tonghua Dongbao and 2024 Research Tax Credit of €2.8 million received in July 2025
Current... ► Artikel lesen | |
| 16.07. | ADOCIA Announces Half-Year Report on Adocia's Liquidity Agreement with Kepler Capital Markets | 483 | Business Wire | Regulatory News:
Under the liquidity agreement entrusted by Adocia (Euronext Paris: FR0011184241 ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on... ► Artikel lesen | |
| 11.07. | Number of Shares and Voting Rights of ADOCIA as of June 30th, 2025 | 382 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen | |
| 24.06. | ADOCIA Presentations at ADA & IPITA Scientific Conferences Highlight Scalability and Good Translation of AdoShell from Human Islets to Stem Cell-Derived Islets | 392 | Business Wire | Main results are:
successful scale up from animal to human device for First-In-Human study
in vitro and in vivo maturation after encapsulation of immature stem cell-derived islets in... ► Artikel lesen | |
| 12.06. | ADOCIA SA: Number of Shares and Voting Rights of ADOCIA as of May 31st, 2025 | 405 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen | |
| 22.05. | ADOCIA Confirms its Eligibility for the PEA-PME Scheme | 444 | Business Wire | Regulatory News:
Adocia (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment... ► Artikel lesen | |
| 21.05. | ADOCIA Announces its Annual Shareholders' Meeting to be Held on June 11th, 2025 in Paris | 439 | Business Wire | Regulatory News:
Adocia (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment... ► Artikel lesen |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,35 | +0,68 % | BIONTECH SE ADR - Stabilität als strategisches Signal | ||
| EVOTEC | 5,450 | +0,26 % | Stock Picking Alarm! Power Metallic Mines - Verdoppler? Puma und Evotec als chancenreiche Turnarounds? | Das Börsenjahr 2025 hat viele Gewinner, aber auch Verlierer hervorgebracht. Haussierende Rohstoffmärkte und Projektfortschritte haben zu Beginn des Jahres zu einem Kurssprung des kanadischen Rohstoffunternehmens... ► Artikel lesen | |
| BB BIOTECH | 48,600 | -0,31 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| MEDIGENE | 0,022 | -20,00 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| QIAGEN | 38,855 | +0,26 % | QIAGEN N.V.: QIAGEN gibt Details zum Abschluss des synthetischen Aktienrückkaufs über bis zu rund $500 Mio. bekannt | Kapitalrückzahlung durch synthetischen Aktienrückkauf kombiniert schnelle, unmittelbare Kapitalrückzahlung an Aktionärinnen und Aktionäre mit einer Aktienzusammenlegung zur Steigerung des Gewinns... ► Artikel lesen | |
| CUREVAC | 3,620 | +0,11 % | Morgen-Update: Curevac-Aktie tritt auf der Stelle - Anleger warten auf das nächste Signal. | ||
| MODERNA | 26,525 | +0,25 % | Forget Moderna Stock, This is a Much Better Buy | ||
| VALNEVA | 3,762 | +1,51 % | Valneva Aktie: 2 Euro oder 8 Euro - wo liegen die nächsten Ziele? | Die Valneva Aktie hat turbulente Jahre mit einem Kurssturz auf 1,726 Euro hinter sich gebracht. Der Aktienkurs des französischen Impfstoff-Entwicklers befindet sich seit Ende 2024 aber wieder in einer... ► Artikel lesen | |
| AMGEN | 280,75 | +0,20 % | Amneal Pharma, MAbxience: FDA Approves Denosumab Biosimilars Referencing Amgen's Prolia And XGEVA | THOUSAND OAKS (dpa-AFX) - Amneal Pharmaceuticals, Inc. (AMRX) announced late Monday that the U.S. Food and Drug Administration has approved the Biologics Licensing Applications or BLAs for Boncresa... ► Artikel lesen | |
| EPIGENOMICS | 0,900 | +2,27 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 5,792 | -0,12 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| STRYKER | 298,50 | -0,33 % | Stryker Earnings Preview: What to Expect | ||
| BIOGEN | 146,60 | -2,46 % | Biogen Inc.: The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS | Long-term data published in JAMA Neurology further illustrate the effects of Biogen's QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained... ► Artikel lesen | |
| BIOFRONTERA | 2,440 | 0,00 % | PTA-news: Biofrontera AG: Biofrontera berichtet über die Ergebnisse der ersten neun Monate des Jahres 2025 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DER ERSTEN NEUN MONATE DES JAHRES 2025
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,420 | +0,41 % | EQS-News: Heidelberg Pharma AG: Brief des Vorstandsvorsitzenden | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Sonstiges
Heidelberg Pharma: Brief des Vorstandsvorsitzenden
17.12.2025 / 09:21 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen |
Das Unternehmen ADOCIA SAS kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,580 Euro und damit +2,81 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADOCIA SAS finden Sie auf Wallstreet Online.